nature neurOSCIenCe a r t I C l e S The human genome contains ~800 odorant receptor genes that have been shown to exhibit high genetic variability 1-3 . In addition, humans exhibit considerable variation in the perception of odorants 4,5 , and variation in an odorant receptor predicts perception in four cases: loss of function in OR11H7P, OR2J3, OR5A1 and OR7D4 leads to elevated detection thresholds for the respective agonists isovaleric acid 6 , cis-3-hexen-1-ol 7 , β-ionone 8 and androstenone 9 . These results suggest that although the olfactory system uses a combinatorial code in which responses of multiple receptor types lead to recognition of a given odorant, the response of a single receptor can have a large influence on the perception of an odorant.
a r t I C l e S The human genome contains ~800 odorant receptor genes that have been shown to exhibit high genetic variability [1] [2] [3] . In addition, humans exhibit considerable variation in the perception of odorants 4, 5 , and variation in an odorant receptor predicts perception in four cases: loss of function in OR11H7P, OR2J3, OR5A1 and OR7D4 leads to elevated detection thresholds for the respective agonists isovaleric acid 6 , cis-3-hexen-1-ol 7 , β-ionone 8 and androstenone 9 . These results suggest that although the olfactory system uses a combinatorial code in which responses of multiple receptor types lead to recognition of a given odorant, the response of a single receptor can have a large influence on the perception of an odorant.
Understanding the role of a single receptor requires functional data for receptor-odorant pairs. Matching mammalian odorant receptors to ligands has seen limited success, and the picture is even worse when considering human odorant receptors; ligands have been published for only 22 of the ~400 intact human odorant receptors 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . This lack of data is a critical bottleneck in the field; matching ligands to odorant receptors is essential for understanding the olfactory system at all levels and for building viable models of olfaction.
Using a high-throughput system for functional testing of odorant receptors 18 , we can now study the role of missense single-nucleotide polymorphisms (SNPs) in the function of odorant receptors. Here we identify ligands for several orphan odorant receptors, determine the prevalence and functional consequences of missense mutations in odorant receptors, and measure the effect of these functional changes on human olfactory perception.
RESULTS

High-throughput screening of human odorant receptors
To identify agonists for a variety of odorant receptors, we cloned a library of 511 human odorant receptor genes for a high-throughput heterologous screen. These clones represent 394 (94%) of the 418 intact odorant receptor genes, and 428,793 (47%) of their 912,912 intact odorant receptor alleles present in the 1000 Genomes Project. Some odorant receptors were represented by multiple nonsynonymous alleles in the screen.
We screened the odorant receptor library with a panel of 73 odorants that have been used in previous psychophysical testing 9, 19 and used a cyclic adenosine monophosphate (cAMP)-mediated luciferase assay to measure receptor activity 20 (Supplementary Fig. 1) . In the primary screen, we stimulated at an odorant concentration of 100 µM. We selected 1,572 odorant-receptor pairs from this primary screen for a secondary screen in which we tested each odorant receptor against a no-odor control as well as 1 µM, 10 µM and 100 µM concentrations of the odorant in triplicate. For 425 odorant-receptor pairs, exposure to at least one concentration of the odorant resulted in significantly higher activation than the no-odor control (t-test, P < 0.05, uncorrected for multiple comparisons). These odorant-receptor pairs included 190 clones representing 160 unique odorant receptors.
We then constructed dose-response curves for at least one putative agonist of 160 odorant receptors. 27 odorant receptors showed a significant response to at least one agonist (extra sums-of-squares F test against vector control, P < 0.05 divided by the number of Humans have ~400 intact odorant receptors, but each individual has a unique set of genetic variations that lead to variation in olfactory perception. We used a heterologous assay to determine how often genetic polymorphisms in odorant receptors alter receptor function. We identified agonists for 18 odorant receptors and found that 63% of the odorant receptors we examined had polymorphisms that altered in vitro function. On average, two individuals have functional differences at over 30% of their odorant receptor alleles. To show that these in vitro results are relevant to olfactory perception, we verified that variations in OR10G4 genotype explain over 15% of the observed variation in perceived intensity and over 10% of the observed variation in perceived valence for the high-affinity in vitro agonist guaiacol but do not explain phenotype variation for the lower-affinity agonists vanillin and ethyl vanillin. a r t I C l e S receptors tested), including nine that have previously been shown to respond to at least one agonist 9, 16, 17 (Fig. 1) . For the other 18 odorant receptors we identified new agonists. This nearly doubles the total number of published human odorant receptors with known agonists, bringing the total to 40 (refs. 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . The receptors identified by this method are spread throughout 9 of the 13 gene families of odorant receptors 21 (Fig. 2) , suggesting that our assay is useful for examining ligand-receptor interactions across a wide variety of odorant receptors.
Genetic variation in odorant receptors
We identified agonists for seven odorant receptors that segregate between intact and disrupted forms ( Table 1) , bringing the total number of segregating pseudogenes with known agonists to eight 6 . Combined with psychophysics data for a genotyped population, these odorant receptor-agonist pairs can be used to probe the role of a single odorant receptor in olfactory perception.
In addition to segregating pseudogenes and missense variation in conserved amino acid residues, a segregating missense variation that alters nonconserved amino acid residues of odorant receptors can also account for a portion of the variance in odor perception [7] [8] [9] . How many of the odorant receptors with intact open reading frames have functionally different variants, adding to the already considerable amount of variation in the human odorant receptor repertoire? We found a median of five alleles with an allele frequency greater than 1% across 418 odorant receptors in the 1000 Genomes Project data. 18 odorant receptors had only one allele with an allele frequency over 1% across the 2,184 haplotypes. In contrast, OR51A2 had 19 different variants with an allele frequency over 1%. The odorant receptors for which we identified agonists did not exhibit a significantly different number of polymorphisms than odorant receptors without identified agonists (median alleles = 5 for both sets, two-sided Mann-Whitney U test, Z = 0.77, P = 0.44).
To test how variability in amino acid sequence affects odorant receptor activation by odorants, we targeted odorant receptors with at least one known agonist and cloned alleles from pooled genomic DNA with the goal of representing the majority of proteincoding alleles seen in the 1000 Genomes Project data. For 16 odorant receptors we successfully cloned 51 alleles, which represented an average of 27,118 (77%) of the receptors' 34,944 alleles present in the 1000 Genomes Project data. One mechanism through which genetic polymorphisms could influence receptor function is by altering cell-surface expression. We assessed the cell-surface expression of odorant receptor variants encoded by these 51 cloned alleles using live-cell immunostaining with an antibody against the N-terminal Rho tag followed by fluorescenceactivated cell sorting (FACS). Relative cell-surface expression among each set of variants did not correlate with either relative potency (Spearman ρ = 0.04, P = 0.82, Supplementary Fig. 2a ) or relative efficacy (Spearman ρ = 0.13, P = 0.45, Supplementary Fig. 2b ) of the variants in the functional assay. Although a complete lack of cellsurface expression eliminated receptor responses to known agonists, high surface expression did not reliably confer additional sensitivity. Supplementary Table 1 . Figure 2 Unrooted tree based on similarity of amino acid properties. 27 odorant receptors with agonists are highlighted in red and represent 9 of the 13 odorant receptor gene families. Grantham's amino acid property scales were used to quantify receptor similarity 30 , and distances were calculated using the unweighted pair group method with arithmetic mean (UPGMA). npg a r t I C l e S A small amount of cell-surface expression was sufficient to confer functional responses. In summary, FACS did not provide enough resolution to determine whether functional variation was due to defects in cell-surface expression.
Functional consequences of genetic variation
We screened odorant receptor variants encoded by 46 of the alleles used in the FACS analysis against 55 odorants chosen quantitatively to span the physicochemical space 17 (Supplementary Fig. 3 ). Across odorants, the absolute magnitudes of response varied, but the relative responses of variants remained consistent ( Fig. 3a,b and Supplementary Fig. 4) . In other words, if a variant was hypersensitive to one agonist, that variant tended to be hypersensitive to all agonists. We found no case of a genetic change that resulted in a change in odor tuning ( Supplementary Fig. 4 ), but we chose our odorant library to span odorant space, and this library was therefore not ideal for identifying more subtle changes.
We then examined how the variant responses compared across a range of concentrations by constructing a dose-response curve from 10 nM to 10 mM ( Fig. 3c and Supplementary Fig. 5 ). Here we included the 15 odorant receptors tested against all 55 odorants as well as 12 additional odorant receptors. We typically used only a single agonist, as our results from using a broad set of odorants suggested that the differences between variants using one odorant were highly correlated to differences between variants using different odorants. We fit the data to a sigmoid curve and compared the variants using an extra sums-of-squares F test. We classified a pair of variants as hyper-or hypofunctional if one variant in the pair had both a lower potency (half maximal effective concentration; EC50) and a lower efficacy (maximum value). Comparing one variant to all other variants of the same odorant receptor from the 1000 Genomes Project data revealed that 11% of the variants were hyperfunctional, 68% were indistinguishable and 6.8% were hypofunctional. 7.9% of the variants were encoded by pseudogenes, and for 5.5% of the variants, potency and efficacy did not change concordantly, so we could not clearly classify them as hypo-or hyperfunctional ( Fig. 4a) . 63% (17/27) of the odorant receptors we examined had polymorphisms that altered in vitro function. Residues that are polymorphic across variants with measured function are shown in Figure 4b . There was no obvious pattern to the amino acids that change function; they were found throughout the protein. The odds that a residue altered function in our assay did not correlate with evolutionary conservation (genomic evolutionary rate profiling (GERP) score, regression analysis, r = −0.04, P = 0.83), predictions from the SIFT tool (sorting intolerant from tolerant; regression analysis, r = 0.05, P = 0.80) or predictions from the PolyPhen tool (polymorphism phenotyping; regression analysis, r = −0.05, P = 0.81).
To quantify functional differences across the 1000 Genomes Project population, we assigned in vitro results to each participant according to their allele type. We had in vitro results for 46,561 (79%) of the 58,968 alleles (27 odorant receptors × 1,092 subjects × 2 alleles). When we conservatively classified all pairwise comparisons, including those involving untested alleles, as functionally identical, we saw an average of 16 functional differences in dose response out of 54 possible functional differences (27 odorant receptors tested in dose response × 2 alleles; Fig. 5a ). When we classified all pairwise comparisons, including an untested allele, as functionally different, we saw an average of 22 functional differences in dose response out of 54 possible functional differences. These results were consistent The frequency of disrupted alleles for the corresponding odorant receptor genes as found in the 1000 Genomes Project 22 is listed. In cases where the variant allele alters a highly conserved domain in the protein, the conserved amino acid that varies is underlined. npg a r t I C l e S (median Asian = 13; median non-Asian = 17; two-sided Mann-Whitney U test, z = 127, P < 0.0001). Pairs in which both participants were of African ancestry (African Ancestry in Southwest United States (ASW), Luhya in Webuya, Kenya (LWK), and Yoruba in Ibadan, Nigeria (YRI)), were more functionally different than pairs in which neither participant was of African ancestry (median African = 16; median non-African = 15; two-sided Mann-Whitney U test, z = 29, P < 0.0001) 22 , in line with those populations having a greater genetic diversity (Fig. 5b) . However, when taking genetic diversity into account, pairs in which both participants were of African ancestry (ASW, LWK and YRI) were more functionally similar than pairs in which neither participant was of African ancestry (median African = −0.83; median non-African = 0.36; two-sided Mann-Whitney U test, z = 149, P < 0.0001; Fig. 5c ). This shows that, although there is greater genetic variability among individuals of African descent, much of this diversity did not translate into functional differences relative to other groups.
Perceptual consequences of genetic variation
We have so far shown that genetic changes are widespread in the human population and that these genetic changes result in widespread in vitro functional changes. We next determined whether the observed in vitro functional changes lead to the predicted consequences in perception. We selected an odorant receptor encoded by OR10G4 for additional testing because we had genomic DNA of subjects that had been tested for their perception of three agonists of the OR10G4 receptor 19 and because functional and nonfunctional OR10G4 alleles were common in the 1000 Genomes Project data 22 . We obtained OR10G4 sequences for 308 of the 391 participants who had rated their perceived intensity and valence for guaiacol, vanillin and ethyl vanillin. We then examined the effect of each OR10G4 allele on the perceptual phenotypes ( Fig. 6) .
There were four OR10G4 alleles with minor allele frequency (MAF) >4% in the participant population: the reference allele (allele 1), which encodes ALTYMGPVRK, and variant alleles 2-4 that encode products that differ from the one encoded by the reference allele by two (APTYMGPERK), five (VLTYVGPEGQ) or eight (ALICVSSEGQ) amino acids, respectively. We challenged the odorant receptor variants encoded by these four alleles with guaiacol using a heterologous luciferase assay and fit the resulting data to a sigmoidal curve. The odorant receptor encoded by allele 2 was more sensitive to guaiacol than the reference odorant receptor encoded by allele 1, but the effect was small (log(EC50 for allele 1) = −7.4, log(EC50 for allele 2) = −7.7, extra sum of squares F test, F 3,42 = 6.38, P < 0.002). The odorant receptor encoded by allele 3 had a much lower affinity to the three odorants than the reference odorant Fig. 6a ). We generated odorant receptors with each of the SNPs in a reference background and found that no single SNP accounted for the functional impairment in the odorant receptors encoded by alleles 3 and 4, suggesting that multiple residues interact to cause the decrease in affinity (Supplementary Fig. 6 ).
Using multiple regression analysis, we tested whether OR10G4 allele type significantly predicted participants' perception of the three in vitro agonists. We regressed the predictors, allele counts (0, 1 or 2) for the four alleles with frequency >4% in the participant population, against the odor rating rank. OR10G4 allele type predicted 15.4% of the variance in perceived intensity of guaiacol (regression analysis, r 2 = 0.165, adjusted r 2 = 0.154, compared to constant model, F 4,303 = 15.0, P < 0.001 after false discovery rate (FDR) correction). The model estimated that subjects with none of the major alleles would rank the intensity of guaiacol 24th relative to the other tested odors. Participants rated guaiacol 2.1 ranks more intense for each copy of the reference allele 1 they possessed (β = 2.10, P < 0.04), and 2.4 and 4.3 ranks less intense for each copy of alleles 3 and 4 they possessed (β = −2.39, P < 0.02 and β = −4.34, P < 0.005), respectively. Participants' intensity ratings were not significantly associated with possession of allele 2 (β = 1.01, P = 0.32).
In addition to intensity, OR10G4 allele type predicted 10.3% of the variance in perceived valence of guaiacol (r 2 = 0.115, adjusted r 2 = 0.103, compared to the constant model, F 4,303 = 9.85, P < 0.001 after FDR correction). The model estimated that subjects with none of the major alleles would rank the valence of guaiacol 29th relative to the other tested odors. Participants rated guaiacol 3.3 and 3.7 ranks more pleasant for each copy of alleles 3 and 4 (β = 3.33, P < 0.002 and β = 3.71, P < 0.03), respectively, but participants' valence ratings were not significantly associated with possession of alleles 1 and 2 (β = −0.69, P = 0.52; β = 1.88, P = 0.08), respectively.
In contrast to guaiacol, neither perceived intensity nor valence of vanillin and ethyl vanillin were predicted by OR10G4 allele type (vanillin intensity compared to the constant model, F 4,303 = 0.95, uncorrected P = 0.44; ethyl vanillin intensity compared to the constant model, F 4,303 = 0.95, uncorrected P = 0.44; vanillin valence compared to the constant model, F 4,303 = 0.84, uncorrected P = 0.50; and ethyl vanillin valence compared to the constant model, F 4,303 = 0.50, uncorrected P = 0.74). As additional controls, the 308 participants were also psychophysically tested for their intensity and valence perception of 63 odors that are not known to be agonists of the OR10G4 receptor as well as two solvents. Of the 68 compounds, only guaiacol intensity and valence were significantly correlated with OR10G4 allele type (Fig. 6c,d) .
DISCUSSION
We identified 27 odorant receptors with known agonists that have functionally different alleles that segregate in the human population and demonstrated that this segregation is relevant to human perception of odorants. This nearly doubles the number of human odorant receptors with a known agonist and, to our knowledge, is the first investigation of the functional role of genetic variation in a large set of odorant receptors. Pairing odorants and odorant receptors, and verifying the functional consequences of segregating polymorphisms in vitro allowed us to address previously inaccessible questions regarding how activation of an individual odorant receptor alters olfactory perception. This promises to be a rich future field of study, as we do not currently know how the odorant receptor array codes for odor threshold, intensity or character. Understanding how the functional alteration of an odorant receptor affects the neural code is a crucial first step in a model of olfactory perception.
Each pair of individuals had, on average, differences in 16-22 of a possible 54 alleles (27 odorant receptor genes with dose-response data × 2 alleles per subject). If we extrapolate to the ~400 intact odorant receptors, we expect each pair of individuals to differ at 237-326 of the 800 alleles. This suggests that odor detection at the peripheral level is highly variable. Variation at the peripheral level leads to variability in odor perception across individuals in several cases; in addition to the OR10G4-guaiacol association we demonstrated here, four olfactory perceptual phenotypes have previously been linked to a single odorant receptor genes [6] [7] [8] [9] and five additional olfactory phenotypes have been linked to regions of the genome containing genes encoding more than one receptor [23] [24] [25] . Each individual, therefore, has a highly personalized set of olfactory receptors that affects his or her perception of odors.
We focused only on SNPs in the coding regions of the odorant receptor genes because of the lack of an efficient assay for testing the effects of noncoding polymorphisms on expression. That said, there is considerable variation in noncoding regions, which can lead to altered gene transcription 26 and even changes in sensory perception 27 . Similarly, we did not examine copy-number variation, which is widespread in human odorant receptors 28, 29 . Thus, our data underestimate the potential extent of variation in each individual's expressed odorant receptor repertoire.
Our study did not find any evidence suggesting SNPs that alter in vitro function are restricted to a particular domain of the receptor, deviate from neutral evolution or are predicted by two popular computational alogrithms. Note, however, that our study was not designed to carefully detect changes resulting from a particular SNP; because we did not generate every possible combination of SNPs for the majority of odorant receptors, SNP-specific alterations may be confounded by linkage in the tested alleles.
Although we found that OR10G4 has at least three in vitro agonists, the OR10G4 allele type only predicted perceived intensity and valence for guaiacol. The dose-response curves shown in Figure 6a reveal that guaiacol is a more potent agonist than either vanillin or ethyl vanillin. Although more data are needed, one possible interpretation is that the intensity and valence of odorants that only weakly activate a receptor will not be altered by functional variation in the receptor. Indeed, this is similar to the association between OR7D4 genotype and androstenone 9 . In that case, the receptors encoded by both of the major alleles respond to androstenone in vitro, but one variant is much less potent than the other. As was the case for OR7D4, participants with the allele that encoded a receptor with lower in vitro affinity to the ligand found the odor to be less intense and more pleasant. This suggests that not all functional variation in vitro will lead to perceptual variation, but the exact rules determining how much of this variation is compensated for at later stages of processing will require further investigation.
Variation in OR10G4 genotype explains 15.4% of the variance in perception of guaiacol intensity, which is lower than the 39% of variation in perception of androstenone intensity explained by variation in OR7D4 genotype. The reason for this lower explanatory value is unclear. One possibility is that more odorant receptors have a role in the perception of guaiacol than in the perception of androstenone, therefore reducing the influence of a single odorant receptor on the percept. Another is npg a r t I C l e S that confounding variables, such as culture and genetic background, may have differential effects on the two phenotypes.
The role of a single odorant receptor in olfactory perception is currently unknown, in part because of the large search space for both odorants and odorant receptors, and the redundant nature of the combinatorial code for odorant identity. By assigning ligands to odorant receptors, measuring the functional consequences of segregating polymorphisms in vitro and linking in vitro function to human behavior, these data provide a solid platform from which to probe the effects of a single odorant receptor on olfactory perception.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
cloning.
Odorant receptor open reading frames were amplified from the genomic DNA of 20 participants from the International Hapmap Consortium using Phusion polymerase and subcloned into pCI expression vectors (Promega) containing the sequence encoding the first 20 residues of human rhodopsin (Rho tag). The sequences of the cloned receptors were verified by sequencing (3100 Genetic Analyzer, Applied Biosystems).
Fluorescence-activated cell sorting. We conducted FACS analysis on all tested clones for the 17 odorant receptors where we had more than one clone (Supplementary Fig. 5 ). Hana3A cells were maintained in minimal essential medium (Sigma) containing 10% FBS (Sigma), 500 µg/ml penicillin-streptomycin (Invitrogen) and 6 µg/ml amphotericin B (Sigma). Cells were seeded in 35-mm dishes (Falcon) and grown overnight at 37 °C and 5% CO 2 . The following day, each dish was transfected with plasmids using 4 µl Lipofectamine 2000 (Invitrogen), 1,200 ng Rho-tagged odorant receptor plasmid, 300 ng human receptortransporting protein 1 short (RTPIS) plasmid and 20 ng of EGFP plasmid to control for transfection efficiency. 24 h after transfection, cells were washed with PBS and detached from the dishes using Cellstripper (Cellgro). Primary incubation was carried out at 4 °C using mouse monoclonal anti-rhodopsin 4D2 (ref. 31 ; gift from R. Molday) diluted 1:50 in PBS containing 2% FBS and 15 mM NaN 3 for 30 min. Cells were washed in PBS containing 2% (vol/vol) FBS and 15 mM NaN 3 , followed by secondary incubation with Phycoerythrin (PE)-conjugated donkey antimouse antibody (Jackson Immunologicals) diluted 1:100 in PBS containing 2% FBS and 15 mM NaN 3 for 30 min, covered with aluminum foil. Cells were washed and resuspended in PBS containing 2% FBS and 15 mM NaN 3 containing 1:500 dilution of 7-aminoactinomycin D (7AAD; 1 mg/ml; Calbiochem), a fluorescent, cell-impermeant DNA-binding agent that selectively stains dead cells. Sorting of fluorescent cells was conducted using a BD FACSCanto (BD Biosciences). Cells that were EGFP-negative and/or 7AAD-positive were removed from subsequent analysis. Cell-surface expression was quantified as PE fluorescence intensity. Data collection and analysis were not randomized. luciferase assay. The Dual-Glo Luciferase Assay System (Promega) was used to measure receptor reponses as previously described 20 . Hana3A cells were transfected with 5 ng/well of RTP1S plasmid 32 , 5 ng/well of pRL-SV40, 10 ng/well of luciferase driven by a cyclic AMP response element, 2.5 ng/well of M3 (ref. 33 ) and 5 ng/well of plasmids encoding odorant receptors. 1 M odorant stocks were diluted in DMSO. 24 h after transfection, transfection medium was removed and replaced with the appropriate concentration of odor diluted from the 1 M stocks in CD293 (Gibco). Four hours after odor stimulation, luminescence was measured using a Polarstar Optima plate reader (BMG). All luminescence values were divided by the Renilla luciferase activity to control for transfection efficiency in a given well. Data were analyzed with Microsoft Excel, GraphPad Prism 4 and Matlab (MathWorks). 1000 genomes Project data. Allele frequency in the human population was derived from the May 2011 phased release of the 1000 Genomes Project public data (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/) 22 . Variant calls were obtained from the public repository in vcf format using tabix 34 . A custom-written Matlab script was used to translate the vcf file into 2,184 full-length phased alleles (two alleles for each of the 1,092 participants in the public database).
Human odorant receptor genotyping. All DNA samples were approved by the Rockefeller University Institutional Review Board. All subjects gave informed consent to participate and were financially compensated for their time and effort. Venous blood (8.5 ml) was collected from participants and genomic DNA was prepared with the Qiagen PAXgene blood DNA kit. For sequencing, human genomic DNAs were amplified with HotStar Taq (Qiagen) with primers upstream (5′-ACCTGGTTGATGCAGTTTCC-3′) and downstream (5′-AAACCTATTGA TGAGAAATGAGTCAA-3′) of the OR10G4 open reading frame. The PCR products were then purified using Sephacryl S-400 (GE Healthcare) and sequenced with a 3100 or 3730 Genetic Analyzer (ABI Biosystems).
Procedures for olfactory psychophysics. All psychophysical data were obtained from ref. 19 and approved by the Rockefeller University Institutional Review Board. All subjects gave informed consent to participate and were financially compensated for their time and effort. Exclusion criteria for subjects were: allergies to odors or fragrances, a history of nasal illness, upper respiratory infection, seasonal allergy, prior endoscopic surgery on the nose, preexisting medical condition that has caused a reduced sense of smell such as head injury, cancer therapy, radiation to head and neck, or alcoholism. Pregnant women and children under 18 were excluded from this study. Of the 308 subjects (138 male), 133 were Caucasian, 29 were Asian and 77 were African-American. The median age was 35 years, with a range of 19 to 66. In brief, participants rated the intensity and valence of 66 odorants on a 7-point scale. The intensity scale was labeled with 1 as "extremely weak" and 7 as "extremely strong. " The valence scale was labeled with 1 as "extremely unpleasant" and 7 as "extremely pleasant. " Stimuli were presented in jars. For a detailed description of the psychophysical methods, see ref. 9 . Three of these odorants, ethyl vanillin, vanillin and guaiacol, are in vitro agonists to OR10G4. We examined the ratings of the higher of two tested concentrations. Ethyl vanillin and vanillin were presented at a 1/200 dilution in propylene glycol; guaiacol was presented at a 1/1,000,000 dilution in paraffin oil. Our data collection and analysis was blind to genotype, as all sequencing was conducted after phenotyping of the human subjects was complete. Data collection and analysis were not randomized.
Statistical analysis. Screening procedure. We stimulated the entire odorant receptor library with 73 odorants used in previous psychophysical testing 9 . We applied the odorants at 100 µM (except for androstenone and androstadienone, which were both applied at 10 µM) and ranked odorant-receptor pairs by their activity above the no-odor condition. We selected the top 5% of odorant-receptor pairs from this primary screen; some receptors were very promiscuous, so we tested only the top ten ligands for a given receptor. We then performed a secondary screen in which each odorant receptor was tested against a no-odor control as well as 1 µM, 10 µM and 100 µM of agonists identified in the primary screen. Each comparison was performed in triplicate, where each measure was collected from separate wells, but each well contains cells from the same parent plate of cells. Statistical significance was assessed by two-sided t-test comparing the three wells stimulated with odor with the three wells stimulated with medium alone. As this was a screening procedure, the data distribution was assumed to be normal, but this was not formally tested. In addition, the tests were uncorrected for multiple comparisons. We then constructed dose-response curves using concentrations ranging from 10 nM to 10 mM for the odor-receptor pairs that were significantly different from baseline in the secondary screen (t-test, P < 0.05, uncorrected for multiple comparisons). Each odorant receptor-odorant dose was tested in triplicate, where each measure was collected from separate wells, but each well contained cells from the same parent plate of cells, and a vector-only control was included for each odorant. We fit the data to a sigmoidal curve. We counted an odorant as an agonist if the 95% confidence intervals of the top and bottom parameters did not overlap, the s.d. of the fitted log(EC50) was less than 1 log unit and the extra sums-of-squares test confirmed that the odorant activated the receptor significantly more than the control, which was transfected with an empty vector (extra sums-of-squares F test against the vector control, P < 0.05). Data collection and analysis were not randomized.
Screening 55 odorants. To choose 55 odorants that quantitatively span chemical space, we generated 20 physicochemical descriptors that predict 62% of the variance in mammalian odorant receptor responses 17 for 2,715 commonly used odorants. We then divided the 2,715 odorants into 55 clusters using k-means clustering. For each cluster, we selected the odorant closest to the centroid of the cluster among odorants that are previously shown to activate at least one odorant receptor. If no such agonist was present in the cluster, we selected the odorant closest to the centroid of the cluster to maximize structural diversity. Each odorant was screened against each receptor variant at 100 µM in triplicate where each measure was collected from separate wells but each well contains cells from the same parent plate of cells. We performed an analysis of variance (ANOVA) on the responses from the clones of each odorant receptor. We used 15 odorant receptors where we had more than one allele cloned with an allele frequency greater than 1% in the 1,092 participants and the cloned alleles represented a large percentage of the 2,184 alleles. For 13 odorant receptors, the cloned alleles represented more than 85% of the 2,184 alleles. For OR2B11, the cloned alleles represented 37.5% of the alleles, and for OR10G4, the cloned alleles represented 29.5% of the alleles. Data collection and analysis were not randomized.
Dose-response curves. We tested odorant receptors with odorants ranging in concentration from 10 nM to 10 mM. All numerical results are reported as npg mean ± s.e.m. and represent data from a minimum of three replicates, where each measure was collected from separate wells, but each well contains cells from the same parent plate of cells. We fit the resulting data with a three-parameter logistic model. We counted an odorant as an agonist if the 95% confidence intervals of the top and bottom parameters did not overlap, the s.d. of the fitted log EC50 was less than 1 log unit and the extra sums-of-squares test confirmed that the odorant activated the receptor significantly more than was the case for the vector-only control (extra sums-of-squares F test against the vector control, P < 0.05).
For each pair of alleles, we determined whether one model fit the data from both alleles better than two separate models using the extra sums-of-squares test. A pair of alleles was classified as hyper-or hypofunctional if one allele in the pair had both a higher EC50 (lower efficacy) and a lower potency (dynamic range or top-bottom). A pair of alleles was designated as 'unclassified' if the potency and efficacy showed discordant changes (i.e., one allele was more sensitive but had a lower efficacy).
To compare each pair of individuals, we took the four alleles from a single odorant receptor and removed any pairs of alleles that were indistinguishable according to the above criteria. Each remaining pair was counted as one functional difference. These values were summed across odorant receptors, with a maximum of 48 possible functional differences per pair of participants. Data collection and analysis were not randomized.
Odds that a SNP alters function. We aligned the nucleotide sequences of the odorant receptor variants to a multiple-sequence alignment of 1,425 intact mouse and human odorant receptors. For each SNP, we calculated the ratio of the odds that a functional change (as defined above, relative to the most common functional variant) occurred in an allele with a nonsynonymous amino acid to the odds that a functional change occurred in an allele with a synonymous amino acid. We used SNPnexus 35 (Ensembl 63 build) to generate GERP, SIFT and PolyPhen scores.
Multiple linear regression model. Multiple regression analysis was used to test whether the number of OR10G4 alleles significantly predicted participants' perception of the three in vitro agonists. To determine the minimum sample size for this analysis, we performed a Monte-Carlo simulation using the data from ref. 9. We ranked each subject's ratings of the odorants to control for differences in general olfactory acuity and usage for the rating scale across subjects. The predictors were allele counts (0, 1 or 2) for the four alleles with MAF > 4% in the participant population. Data collection and analysis were not randomized.
